Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of EDP-938 in adult hematopoietic cell transplant recipients with acute RSV upper respiratory tract infection
2020-002213-18Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals, Inc.
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing EDP-938 with Placebo (2 arms). Primary endpoint: Incidence of lower respiratory tract complications (LRTC) through Day 28. Started Aug 2020; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2020-002213-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002213-18.